"The new formulation helps protect against the most current strains of SIV," says Michael Kuhn, DVM, MBA, manager, veterinary operations for Pfizer Animal Health. "It is a result of our commitment to surveying the ever-changing landscape of SIV and aggressively updating our vaccines as necessary."
A challenge study evaluating the efficacy of the new formulation containing H1N2 demonstrated FluSure XP helped reduce clinical signs of flu, viral shedding and lung lesions in pigs challenged with Delta 1 H1N2.
Kuhn added: "The vaccine stimulated an antibody response to all strains contained in the vaccine, including the new H1N2 strain. This HI antibody response indicates that updated FluSure XP should help guard against the important flu strains circulating in swine herds today."
Challenge studies have demonstrated that FluSure XP helps provide cross-protection against five clusters or subclusters of H1 viruses, plus H3N2.
New FluSure XP, when used with FluSure® Pandemic as part of the FluSure XP Defense System™, helps guard against 9 out of 10 of the most current flu strains that threaten swine herds today. The FluSure XP Defense System also includes SIV surveillance, diagnostics, research and development, and manufacturing support from Pfizer Animal Health.
Pfizer Animal Health